Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study
Lehtomäki, Kaisa; Stedt, Hanna P.; Osterlund, Emerik; Muhonen, Timo; Soveri, Leena Maija; Halonen, Päivi; Salminen, Tapio K.; Kononen, Juha; Kallio, Raija; Ålgars, Annika; Heervä, Eetu; Lamminmäki, Annamarja; Uutela, Aki; Nordin, Arno; Lehto, Juho; Saarto, Tiina; Sintonen, Harri; Kellokumpu-Lehtinen, Pirkko Liisa; Ristamäki, Raija; Glimelius, Bengt; Isoniemi, Helena; Osterlund, Pia (2022-03)
Lehtomäki, Kaisa
Stedt, Hanna P.
Osterlund, Emerik
Muhonen, Timo
Soveri, Leena Maija
Halonen, Päivi
Salminen, Tapio K.
Kononen, Juha
Kallio, Raija
Ålgars, Annika
Heervä, Eetu
Lamminmäki, Annamarja
Uutela, Aki
Nordin, Arno
Lehto, Juho
Saarto, Tiina
Sintonen, Harri
Kellokumpu-Lehtinen, Pirkko Liisa
Ristamäki, Raija
Glimelius, Bengt
Isoniemi, Helena
Osterlund, Pia
03 / 2022
1713
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202207045975
https://urn.fi/URN:NBN:fi:tuni-202207045975
Kuvaus
Peer reviewed
Tiivistelmä
Metastasectomy and/or local ablative therapy in metastatic colorectal cancer (mCRC) patients often provide long-term survival. Health-related quality of life (HRQoL) data in curatively treated mCRC are limited. In the RAXO-study that evaluated repeated resectability, a multi-crosssectional HRQoL substudy with 15D, EQ-5D-3L, QLQ-C30, and QLQ-CR29 questionnaires was conducted. Mean values of patients in different treatment groups were compared with age-and gender-standardized general Finnish populations. The questionnaire completion rate was 444/477 patients (93%, 1751 questionnaires). Mean HRQoL was 0.89–0.91 with the 15D, 0.85–0.87 with the EQ-5D, 68–80 with the EQ-5D-VAS, and 68–79 for global health status during curative treatment phases, with improvements in the remission phase (disease-free >18 months). In the remission phase, mean EQ-5D and 15D scores were similar to the general population. HRQoL remained stable during first-to later-line treatments, when the aim was no longer cure, and declined notably when tumourcontrolling therapy was no longer meaningful. The symptom burden affecting mCRC survivors’ well-being included insomnia, impotence, urinary frequency, and fatigue. Symptom burden was lower after treatment and slightly higher, though stable, through all phases of systemic therapy. HRQoL was high in curative treatment phases, further emphasizing the strategy of metastasectomy in mCRC when clinically meaningful.
Kokoelmat
- TUNICRIS-julkaisut [16740]